Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies

Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies - Sirolimus for vascular anomalies

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016580

Enrollment

Registered

2015-02-19

Start date

2015-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphangiomatosis, Gorham-Stout disease and vascular anomalies

Interventions

Oral sirolimus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with intaracbtable lymphangiomatosis, Gorham-Stout disease and vascular anomalies

Exclusion criteria

Exclusion criteria: Allergy of sirolimus

Design outcomes

Primary

Measure	Time frame
Improvement of clinical symptoms at 1, 3, 6, 12 after administration	—

Countries

Japan

Contacts

Public ContactMichio Ozeki

Gifu University Pediatrics

michioo@gifu-u.ac.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026